期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Role of the preoperative usefulness of the pathological diagnosis of pancreatic diseases 预览
1
作者 Kazuya Matsumoto Yohei Takeda +5 位作者 Takumi Onoyama Soichiro Kawata Hiroki Kurumi Masaru Ueki Norimasa Miura Hajime Isomoto 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2016年第9期656-662,共7页
Pancreatic cancer is the fifth leading cause of cancer death and has the lowest survival rate of any solid cancer.Endoscopic ultrasound-guided fine-needle aspiration biopsy(EUS-FNA) is currently capable of providing a... Pancreatic cancer is the fifth leading cause of cancer death and has the lowest survival rate of any solid cancer.Endoscopic ultrasound-guided fine-needle aspiration biopsy(EUS-FNA) is currently capable of providing a cytopathological diagnosis of pancreatic malignancies with a higher diagnostic power,with a sensitivity and specificity of 85%-89% and 98%-99%,compared to pancreatic juice cytology(PJC),whose sensitivity and specificity are only 33.3%-93% and 83.3%-100%.However,EUS-FNA is not effective in the cases of carcinoma in situ and minimally invasive carcinoma because both are undetectable by endoscopic ultrasonography,although PJC is able to detect them.As for the frequency of complications such as post endoscopic retrograde cholangiopancreatography pancreatitis,EUS-FNA is safer than PJC.To diagnose pancreatic cancer appropriately,it is necessary for us to master both procedures so that we can select the best methods of sampling tissues while considering the patient’s safety and condition. 展开更多
关键词 Endoscopic ULTRASOUND-GUIDED FINE-NEEDLE aspiration biopsy CYTOLOGY Pathology PANCREATIC JUICE CYTOLOGY PANCREATIC cancer
在线阅读 免费下载
Antifibrotic effects of ambrisentan,an endothelin-A receptor antagonist,in a non-alcoholic steatohepatitis mouse model 预览
2
作者 Toshiaki Okamoto Masahiko Koda +8 位作者 Kennichi Miyoshi Takumi Onoyama Manabu Kishina Tomomitsu Matono Takaaki Sugihara Keiko Hosho Junichi Okano Hajime Isomoto Yoshikazu Murawaki 《世界肝病学杂志:英文版(电子版)》 2016年第22期933-941,共9页
AIM: To examine the effects of the endothelin type A receptor antagonist ambrisentan on hepatic steatosis and fibrosis in a steatohepatitis mouse model.METHODS: Fatty liver shionogi(FLS) FLS-ob/ob mice(male, 12 wk old... AIM: To examine the effects of the endothelin type A receptor antagonist ambrisentan on hepatic steatosis and fibrosis in a steatohepatitis mouse model.METHODS: Fatty liver shionogi(FLS) FLS-ob/ob mice(male, 12 wk old) received ambrisentan(2.5 mg/kg orally per day; n = 8) or water as a control(n = 5) for 4 wk. Factors were compared between the two groups, including steatosis, fibrosis, inflammation, and endothelin-related gene expression in the liver.RESULTS: In the ambrisentan group, hepatic hydroxyproline content was significantly lower than in the control group(18.0 μg/g ± 6.1 μg/g vs 33.9 μg/g ± 13.5 μg/g liver, respectively, P = 0.014). Hepatic fibrosis estimated by Sirius red staining and areas positive for α-smooth muscle actin, indicative of activated hepatic stellate cells, were also significantly lower in the ambrisentan group(0.46% ± 0.18% vs 1.11% ± 0.28%, respectively, P = 0.0003; and 0.12% ± 0.08% vs 0.25% ± 0.11%, respectively, P = 0.047). Moreover, hepatic RNA expression levels of procollagen-1 and tissue inhibitor of metalloproteinase-1(TIMP-1) were significantly lower by 60% and 45%, respectively, in the ambrisentan group. Inflammation, steatosis, and endothelin-related m RNA expression in the liver were not significantly different between the groups.CONCLUSION: Ambrisentan attenuated the progression of hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing procollagen-1 and TIMP-1 gene expression. Ambrisentan did not affect inflammation or steatosis. 展开更多
关键词 ENDOTHELIN AMBRISENTAN STEATOHEPATITIS HEPATIC stellate cell HEPATIC fibrosis Oxidative stress Hepat
在线阅读 免费下载
上一页 1 下一页 到第
使用帮助 返回顶部 意见反馈